Research
Hormonal
GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.
If you have overweight or obesity, GLP-1 and GIP receptor agonists like semaglutide can reduce your risk of cardiovascular events, including death, heart attack, and stroke.
GoodSupportsHIGH confidence
In the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial, patients assigned to the semaglutide group had a lower composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke compared to the placebo group.
Why this rating
Based on the SELECT trial.
Source
Medical Management of Obesity: Current Trends and Future Perspectives
Andrés Calderón et al. · Methodist DeBakey Cardiovascular Journal · 2025
DOI 10.14797/mdcvj.1503
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (15 mg once weekly) combined with lifestyle counseling produces a mean weight loss of 20.9% over 72 weeks in patients with obesity or overweight.Good
- Semaglutide (2.4 mg once weekly) produces a mean weight loss of 14.9% over 68 weeks in patients with obesity without diabetes.Good
- Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →